ESR1 and breast cancer: Beyond TNBC, improved pathologic outcomes with neoadjuvant immunotherapy and chemotherapy have been observed in patients with estrogen receptor-positive and HER2-negative BC as part of the CheckMate-7FL and KEYNOTE-756 clinical trials [5,6].